Authors
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
An Explorer's Mentality Leads to Novel Treatments in Prostate and Bladder CancerAlthough he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.
Latest:
Dr. Noy on Next Phase of a Trial With Devimistat in Relapsed/Refractory Burkitt LymphomaAriela Noy, MD, discusses the next phase of a trial with devimistat in patients with relapsed/refractory Burkitt lymphoma.
Latest:
RET Inhibitor Tested in Multiple Tumor TypesInvestigators are evaluating the potential of LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer, medullary thyroid cancer, and other tumors.
Latest:
Dr. Balar on Results of KEYNOTE-052 in Urothelial CancerArjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.
Latest:
The Patient Is Ready, But the Insurance Is NotTo provide the best care for the patients in front of us, oncologists must once again go above and beyond as needed.
Latest:
Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBCArjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the next steps for research regarding the phase II KEYNOTE-057 trial in nonmuscle–invasive bladder cancer (NMIBC).
Latest:
Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder CancerA major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.
Latest:
Dr. Chan on ExteNET Trial for HER2+ Breast CancerArlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.
Latest:
Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder CancerArlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.
Latest:
Tissue and Liquid Biopsies in Metastatic Urothelial CancerA discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).
Latest:
Dr. Arlene Sharpe on the Role of the PD-1 PathwayArlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the biology of the PD-1 pathway.
Latest:
On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment LandscapeClosing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.
Latest:
Optimizing Precision Medicine in HCCTakeaways from a discussion on treatment advances in hepatocellular carcinoma.
Latest:
The Future of Liver Function Assessments in HCCExperts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.
Latest:
The Awake Craniotomy Presents Advantages in Resection of Eloquent Cortex Brain TumorsAwake craniotomies are traditionally reserved for, but not limited to, tumors involving the primary motor and speech areas
Latest:
Dr Etame on How Patient Socioeconomic Status Affects Cancer CareArnold Etame, MD, PhD, discusses the effects of a patient’s socioeconomic status on the cancer treatment options they receive.
Latest:
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.
Latest:
Pursuing an Oncology Fellowship OverseasPostgraduate fellowship training is an essential cornerstone in medical training.
Latest:
Dr. Naik on Surgical Approaches in Patients With Breast CancerArpana M. Naik, MD, associate professor of surgery, Division of Surgical Oncology, School of Medicine, Oregeon Health and Science University, discusses surgical approaches in the treatment of patients with breast cancer.
Latest:
Dr Desai on the Implications of the CONTACT-03 Trial in RCCArpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.
Latest:
Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal TherapyArt Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.
Latest:
Merging Community Practices With an Academic Cancer CenterConsolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Latest:
Dr. Hurria on Challenges Facing the Geriatric Population with Breast CancerArti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, City of Hope, discusses challenges facing geriatric patients with breast cancer.
Latest:
Dr. Loaiza-Bonilla on Trial of Left- and Right-Sided Colorectal CancerArturo Loaiza-Bonilla, MD, medical oncologist, specializing in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses a clinical trial focused on the differences between left- and right-sided tumors of colorectal cancer (CRC).
Latest:
Dr. Singh on Treatment for Patients With Uterine LeiomyosarcomaArun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses treatment for patients with uterine leiomyosarcoma.
